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Objective: This cross-sectional study sought to determine the prevalence of cardiometabolic risk factor clusters
(CMRFCs) and their effect on BP control among hypertensive patients from 28 US physician practices.
Methods: Each participating practice identified a random sample of 150-300 adults aged ≥ 18 years diagnosed
with hypertension. The primary outcome variable was BP control (BP < 140/90 mmHg for non-diabetic and <130/
80 mmHg for diabetic patients). CMRFCs included hypertension in addition to obesity, dyslipidemia, and diabetes.
Results: Overall, 6,527 hypertensive patients were identified for study inclusion. More than half (54.3%) were
female, and mean age was 64.7 years. Almost half (48.7%) were obese (BMI ≥ 30 kg/m
2). About 1 in every 4
patients (25.3%) had diabetes, and 60.7% had dyslipidemia. Mean blood pressure was 132.5/77.9 mmHg, and 55.0%
of all patients had controlled BP; 62.4% of non-diabetic patients, and 33.3% of diabetic hypertensive patients, had
BP controlled to recommended levels. Most (81.7%) hypertensive patients had ≥ 1 cardiometabolic risk factor, and
12.2% had all 3 risk factors. As compared to hypertensive patients without additional risk factors, adjusted odds
ratios for BP control were significantly lower for all combinations of CMRFCs (ORs 0.15-0.83, all p < 0.04), with the
exception of patients who had only dyslipidemia in addition to hypertension (OR = 1.09, p = NS). Prescriber
adherence to recommended hypertension treatment guidelines for patients with diabetes, heart failure, or prior
myocardial infarction was high. Although patients with risk factors were prescribed more antihypertensive
medications than those without, hypertensive patients with all 3 risk factors were prescribed a mean of 2.4
antihypertensive medications compared to 1.7 for those with no risk factors; odds of BP control in these patients,
however, was 0.23 [95% CI 0.19-0.29] that of patients with no other CMRFCs.
Conclusions: Across 28 US practices, only 18% of hypertensive patients did not have any additional
cardiometabolic risk factors. The high prevalence of CMRFCs presents a challenge to effective hypertension
management.
Background
Almost one-third of adults in the US (29.3%) had hyper-
tension during 2003-04 [1]. Elevated blood pressure
(BP) is a significant contributor to cardiovascular dis-
ease, and is associated with an increased risk of myocar-
dial infarction (MI), stroke, renal failure, and heart
failure. The seventh report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC7) recommends
that all hypertensive non-diabetic patients should be
treated to BP less than 140/90 mmHg, and that all dia-
betic patients should be treated to BP less than 130/80
mmHg [2]. A number of distinct classes of antihyperten-
sive medications are available for the treatment of essen-
tial hypertension, including angiotension-converting
enzyme inhibitors (ACEI), angiotensin-II receptor block-
ers (ARB), beta blockers (BB), calcium channel blockers
(CCB), alpha blockers, direct renin inhibitors, and * Correspondence: jen@medmentis.com
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monly prescribed. JNC7 recommends that a thiazide
diuretic be included as part of the first-line medication
regimen for most patients with hypertension, either
alone or with a medication from another class [2].
Hypertension often co-exists with other metabolic and
cardiovascular chronic conditions, especially diabetes,
obesity, and dyslipidemia. Less than 20% of hypertension
cases occur without one or more concomitant cardio-
vascular risk factors [3]. A cluster of ≥ 2 additional car-
diovascular risk factors occurs in about half of
hypertensive persons [3]. Among hypertensive persons,
about 40% of coronary events in men, and 68% in
women, are attributable to the co-occurrence of two or
more additional risk factors [3]. Almost 1 in 3 US adults
is obese [4]; obesity is associated with increased mortal-
ity, and is responsible for an estimated 111,909 excess
deaths per year [5]. It is estimated that 40% of US
hypertensive patients also suffer from obesity, and 15%
also have diabetes [6]; in addition, 48% of hypertensive
men, and 61% of hypertensive women, also have hyperli-
pidemia [7]. The co-occurrence of hypertension, dia-
betes, hyperlipidemia, and obesity has been referred to
as cardiometabolic risk factor clusters (CMRFCs) [8].
Hypertension treatment guidelines for use of specific
medication classes are based, in part, on the presence of
specific underlying co-morbid conditions. For example,
the use of an ACEI or ARB is the standard of care in
patients with hypertension and diabetes or renal disease
[2]. ACEI/ARB and BB are recommended for use in
patients with heart failure or subsequent to a myocardial
infarction [2]. Use of ACEI in combination with a thia-
zide diuretic is recommended in patients with cerebro-
vascular disease [2]. Current hypertension guidelines do
not include recommendations for specific treatment
regimens in obese hypertensive patients [9]. However,
the use of medications from the beta blocker therapeutic
class in obese patients without specific compelling indi-
cations may not be the optimal choice, as they may
cause weight gain or make weight loss more difficult
[10]. Clearly, the presence of CMRFCs can make the
choice of a treatment regimen fairly complex.
While prospectively designed, randomized studies
remain the “gold standard” for determining the efficacy
and effectiveness of medications, retrospective studies
can provide valuable clinical information among patients
from “usual-care”, non-clinical trial settings. Our study
utilized a retrospective, cross-sectional design to evalu-
ate the prevalence of cardiometabolic risk factors in the
“real-world” physician practice setting, and the subse-
quent impact of these risk factors on BP control. For
the current study, we used a subset of patients from a
large, retrospective cross-sectional study of BP control
and management practices across 28 US physician
organizations. Specifically, we sought to determine the
frequency of co-occurrence of specific cardiometabolic
risk factors - diabetes, obesity, and dyslipidemia- and
the impact of these clusters on BP control among a
diverse cohort of patients diagnosed with hypertension
across the US.
Methods and Procedures
This analysis was part of a larger cross-sectional study
conducted via chart reviews at 28 US physician practices.
Study sites were located across the continental US, with a
concentration in the Southern US (50%) as compared to
the Western (18%), Midwestern (18%), or Northeastern
(14%) census regions of the US. Requirements for site
enrollment included an interest in study participation,
capability to abstract required data elements, and an
adult hypertensive patient population of sufficient size to
allow a random sample of at least 150 patients. Study
data were collected between November 2007 and Sep-
tember 2008 at the point-of-care via data entry by study
investigators at each participating site using a secure
web-based application. Investigators at participating
study sites identified adult patients (≥ 18 years) with a
hypertension diagnosis recorded in the patient’s medical
record (ICD9 code of 401.x or clinical diagnosis from
chart) during the 12 months preceding the date of data
collection at each site, with at least 1 year of visit history
with the physician practice. Pregnant females were
excluded from the study. Site investigators performed a
random sample selection from the entire eligible patient
population to construct a cohort of 150-300 newly- or
previously-diagnosed hypertensive patients.
Information obtained for each patient included age,
gender, and racial/ethnic background; information about
specific risk factors, such as body mass index (BMI; cal-
culated using inputted height and weight), smoking sta-
tus, and documentation of lifestyle modification
counseling (such as weight reduction, dietary changes,
increased physical activity); current antihypertensive
medication regimen; total number of different medica-
tions used for all chronic conditions; and physician spe-
cialty. Specific co-morbid conditions documented in the
patient record were identified using corresponding ICD-
9 codes and/or clinical diagnosis as documented in the
patient’s record; these included coronary arterial disease
(CAD) without myocardial infarction (MI), MI, diabetes,
hyperlipidemia, renal disease, heart failure, and cerebro-
vascular accident/transient ischemic attack.
BP control was the primary outcome variable, and was
defined as BP < 140/90 mmHg for non-diabetic patients,
and <130/80 mmHg for diabetic patients, as measured
at each patient’s most recent visit during the year pre-
ceding the date of data collection. If different measure-
ment techniques were indicated (e.g. sitting, standing, or
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most recent visit date, the sitting measurement was
recorded for study purposes; however, if multiple mea-
surements were recorded on the most recent visit date
without distinction to the method of measurement, the
mean of those values was recorded. JNC-7 classifications
were also used to categorize patients based on BP as
either normal BP (SBP < 120 mmHg and DBP < 80
mmHg), pre-hypertensive (SBP 120-139 mmHg or DBP
80-89 mmHg), stage I hypertension (SBP 140-159
mmHg or DBP 90-99 mmHg), or stage II hypertension
(SBP > 159 mmHg or DBP > 99 mmHg) [2]. In addi-
tion, the BP measurement for the visit immediately pre-
ceding this most recent BP assessment was obtained.
This study was approved and monitored by an inde-
pendent Institutional Review Board. Investigators at
each site were trained on use of the data collection tool
prior to beginning data collection and data entry. Speci-
fic chart abstraction instructions were provided for each
data element as per the study protocol. Site investigators
received a study guide that included detailed instruc-
tions about all data elements, as well as a copy of the
IRB-approved study protocol.
This patient sample was a subset of a larger study
population, which consisted of 8,250 hypertensive
patients from 28 practice sites across the US. The cur-
rent study focused on patients with hypertension and
specific cardiometabolic risk factors; thus, a subset of
the larger study population with complete data for all
cardiometabolic risk factors (n = 6,527) was used for all
analyses described here. Prior to study analyses, a com-
parison of the study population missing specific data
elements versus those not missing each element was
conducted, and analyses of patients with missing versus
non-missing data showed no systematic differences.
Statistical Methods
Univariate descriptive statistics (means and standard
deviations for continuous variables, and frequency distri-
butions for categorical variables) were calculated for all
study variables. Bivariate analyses were also performed;
the chi-square test was used for significance testing for
categorical variables, and analysis of variance and Stu-
dent’s t-tests were used for continuous variables. Logis-
tic regression was used to calculate the odds of BP
control, adjusted for covariates, in the overall study
population and in the subset of patients with co-morbid
diabetes. Variables included in the final regression mod-
els were chosen based on results of bivariate analyses
and clinical significance. Clustering within physicians
and within practices was evaluated, but was determined
to have little impact on odds ratio estimates obtained
v i al o g i s t i cr e g r e s s i o nm o dels. SPSS version 17.0 and
SAS version 8.2 were used for all study analyses.
Results
For this analysis of CMRFC, the cohort included 6,527
hypertensive patients. Demographic and clinical charac-
teristics are included in Table 1. More than half (54.3%)
of the cohort was female. Mean age overall was 64.7
years, and women were significantly older than men (p
< 0.001). Mean BMI was 30.9 kg/m
2,a n da l m o s th a l fo f
study participants (48.7%) were obese (BMI ≥ 30 kg/
m
2). Patients treated by internal medicine specialists
represented 46.9% of the hypertensive study population,
followed by family practice physicians (36.9%) and cardi-
ologists (15.2%). About 1 in every 4 members (25.3%) of
the study cohort had diabetes, and 60.7% had dyslipide-
mia; 4.5% of the cohort had congestive heart failure,
14.3% had CAD without MI, and 7.6% had renal disease.
Mean blood pressure at the most recent measurement
was 132.5/77.9 mmHg. Overall, 55.0% of the study
cohort had controlled BP; 62.4% of non-diabetic patients
had BP controlled, while only 33.3% of diabetic hyper-
tensive patients had controlled BP. Including antihyper-
tensive medications, patients averaged 5.6 (+/-3.6)
different chronic prescription medications, and, on aver-
age, were using a regimen consisting of 2.0 (+/-1.1) anti-
hypertensive classes of medications. Diabetic patients
used a mean of 2.3 (+/-1.2) classes of antihypertensive
medication, compared to 1.9 (+/-1.1) for non-diabetic
patients (p < 0.001). The most commonly used antihy-
pertensive medication classes were diuretics (48.1%),
ACE inhibitors (39.3%), and BB (36.7%). Men were
more likely to be prescribed ACE inhibitors, and women
were more likely to be prescribed ARBs or diuretics (p
< 0.001, all comparisons).
Co-occurrence of cardiometabolic risk factors is
depicted in Figure 1. 81.7% of the 6,527 hypertensive
patients comprising the study cohort were also obese,
had dyslipidemia, and/or had diabetes; only 18.3% had
no concomitant risk factors. Overall, 23.5% had dyslipi-
demia without any other risk factors, 18.0% were obese
and had dyslipidemia, 14.7% were obese only, and 12.2%
had all three cardiometabolic risk factors. Only 2.7% of
patients had diabetes but no other cardiometabolic risk
factors. Non-diabetic patients with dyslipidemia had the
highest rates of BP control among all patients with car-
diometabolic risk factors. BP control rates were lowest
for obese patients with diabetes (23.3%); BP control was
somewhat more common among diabetic patients with
dyslipidemia than for those without, regardless of obe-
sity status. Among hypertensive patients without any
other risk factors, 63.4% had controlled BP. Adjusted
odds ratios for BP control by CMRFC are also shown in
Figure 1. As compared to hypertensive patients without
any additional cardiometabolic risk factors, those with
diabetes, obesity, and dyslipidemia were less likely to
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Furthermore, with the exception of patients with only
dyslipidemia in addition to hypertension, all clusters
were significantly less likely to have controlled BP as
compared to those without any additional cardiometa-
bolic risk factors. Patients with diabetes and obesity
(46.1%) and all 3 cardiometabolic risk factors (37.3%)
w e r et h em o s tl i k e l yt oh a v eaB Pm e a s u r e m e n tt h a t
exceeded goal BP by either 10 or more mmHg systolic
or 5 or more mmHg diastolic (’high risk’ category in
Figure 1). Patients with hypertension and dyslipidemia
only (15.9%) and hypertension without any other cardio-
metabolic risk factors (18.3%) were the least likely to
have BP measurements exceeding this threshold. While
Table 1 indicated a higher prevalence of many comorbid
conditions in men as compared to women, logistic
Table 1 Study population demographic and clinical characteristics by gender
Male (n = 2,955, 45.7%) Female (n = 3,508, 54.3%) Total (n = 6,527)
Age in years (mean, SD) 63.0 (13.2) 66.3 (13.9) (p < 0.001) 64.7 (13.7)
Age groups (%) (p < 0.001)
18-34 years 1.9% 1.2% 1.5%
35-44 years 6.6% 5.0% 5.7%
45-54 years 17.9% 14.8% 16.2%
55-64 years 27.4% 24.3% 25.7%
65-74 years 25.5% 23.9% 24.6%
>74 years 20.7% 30.9% 26.2%
Racial/ethnic background (%) (p < 0.01)
Caucasian 48.0% 45.6% 46.7%
African-American 11.9% 14.9% 13.5%
Hispanic 6.1% 5.5% 5.8%
Unknown/not documented 34.0% 34.0% 34.0%
BMI (kg/m
2 mean, SD) 31.0 (6.3) 30.7 (7.5) (p = 0.06) 30.9 (7.0)
Current smokers (%) 13.5% 9.2% (p < 0.001) 11.2%
Prescribed lifestyle modifications to control BP (%) 61.7% 59.2% (p < 0.05) 60.3%
Co-morbid cardiovascular-related conditions (%)
Obesity (%) 49.8% 47.7% (p=NS) 48.7%
Diabetes 28.0% 23.0% (p < 0.001) 25.3%
Dyslipidemia 65.3% 56.8% (p < 0.001) 60.7%
Congestive Heart Failure 4.0% 4.9% (p = 0.081) 4.5%
CAD without MI 17.2% 11.8% (p < 0.001) 14.3%
CVA/TIA/carotid stenosis 5.2% 4.7% (p=NS) 5.0%
Myocardial Infarction 2.9% 2.1% (p = 0.039) 2.5%
Renal disease/insufficiency 7.8% 7.4% (p=NS) 7.6%
SBP- most recent measurement in mmHg (mean, SD) 132.0 (16.8) 132.8 (16.9) (p = 0.049) 132.5 (16.9)
DBP- prior measurement in mmHg (mean, SD) 78.7 (11.1) 77.2 (10.6) (p < 0.001) 77.9 (10.9)
Physician Specialty (p = 0.027)
Family Practice 35.9% 37.8% 36.9%
Internal Medicine 46.4% 47.3% 46.9%
Cardiology 16.6% 14.0% 15.2%
Other 1.1% 1.0% 1.0%
Total # of medications for all chronic conditions (mean, SD) 5.3 (3.4) 5.9 (3.7) (p < 0.001) 5.6 (3.6)
Total # of antihypertensive medication classes in regimen 1.9 (1.1) 2.0 (1.1) (p=NS) 2.0 (1.1)
Antihypertensive medication use by class (%)
ACE inhibitor 44.9% 34.5% (p < 0.001) 39.3%
ARB 25.6% 29.7% (p < 0.001) 27.8%
BB 36.5% 36.7% (p=NS) 36.7%
CCB 27.6% 29.4% (p=NS) 28.6%
Any diuretic 43.4% 52.1% (p < 0.001) 48.1%
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gender, was a significant predictor of BP control (OR =
0.95, 95% CI 0.86-1.06).
Antihypertensive medication use by CMRFC is shown
in Table 2. Hypertensive patients with obesity, dyslipide-
mia, and diabetes were prescribed the highest mean
number of antihypertensive medications (2.4 +/- 1.2),
while hypertensive patients without any other CMRFCs
had the fewest (1.7 +/- 1.1, p < 0.001). Patients with dia-
betes had higher rates of ACEI or ARB usage than
patients without diabetes, regardless of whether addi-
tional cardiometabolic risk factors were present. Among
patients with 2 risk factors, those with diabetes and dys-
lipidemia who were not obese were least likely to be
prescribed a diuretic, and obese diabetic patients (with-
out dyslipidemia) were least likely to be prescribed BB
(Table 2). Among all patients, use of BB did not appear
to differ between obese (37.7%) and non-obese patients
(35.6%, p=NS). Obese patients were prescribed a greater
number of antihypertensive medications as compared to
non-obese patients (2.1 +/- 1.2 vs 1.8 +/- 1.1, p <
0.001), as were diabetic as compared to non-diabetic
patients (2.3 +/- 1.2 vs 1.9 +/- 1.1, p < 0.001). Patients
with dyslipidemia were also prescribed more antihyper-
tensive medications than those without (2.0 +/- 1.1 vs
1.9 +/- 1.1, p < 0.001). Among the subset of obese
patients with diabetes (n = 1,042), those with controlled
BP were prescribed a similar mean number of antihy-
pertensive medication classes as those with uncontrolled
BP (2.4 +/- 1.2 vs. 2.4 +/- 1.2, p = 0.46). A higher pro-
portion of obese diabetic patients who were prescribed a
regimen containing an ACEI/ARB had controlled BP
than among those not using ACEI/ARB (33.3% vs
25.5%, p < 0.04), unadjusted for clinical and demo-
graphic characteristics. Among this obese diabetic
patient subset, a higher proportion of patients pre-
scribed a regimen containing a CCB had BP controlled
than those not using CCB, although this difference was
not statistically significant (27.7% vs vs 33.7%, p =
0.055).
The relationship between BMI and BP control is
depicted in Figure 2. As BMI increased in our study
Figure 1 Venn diagram of cardiometabolic risk factor clusters (CMRFC) and association with BP control among hypertensive patient
cohort (n = 6,527)*. Among the study hypertensive patient cohort, the co-occurrence of the cardiometabolic risk factors obesity, dyslipidemia,
and diabetes are depicted. Obese hypertensive patients with diabetes had the lowest adjusted odds ratios of BP control.
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decreased. The proportion of patients with controlled
BP was higher for those with BMI categorized as ‘nor-
mal’ (<25 kg/m
2)o r‘overweight’ (25-29 kg/m
2); how-
ever, at BMI ≥ 33 kg/m
2, the proportion with controlled
BP declined, and remained lower than the overall BP
control rate for the study cohort.
Use of specific antihypertensive medication classes by
compelling indications is depicted in Table 3. Patients
with diabetes were significantly more likely to be pre-
scribed an ACEI or an ARB than patients without dia-
betes (78.3% vs 60.8%, p < 0.001), and patients with
heart failure were more likely to be prescribed an ACEI,
ARB, or BB than those without (88.7% vs 80.3%, p <
0.001). 88.3% of patients with a prior MI were pre-
scribed an ACEI, ARB, or BB. However, only 67.7% of
patients with renal disease were prescribed an ACEI or
ARB, and only 14.6% of patients with a history of a
stroke, TIA, or carotid stenosis were prescribed an
ACEI in combination with a thiazide diuretic.
Among the subset of hypertensive patients with dia-
betes (n = 1,656), clinical and demographic characteris-
tics and relationship to BP control is shown in Table 4.
Only 21% of African-American diabetic patients had
controlled BP. Compared to patients with uncontrolled
BP, diabetic patients with controlled BP were older, had
a lower mean BMI, and were using more prescriptions
for all chronic conditions (8.1 vs 7.1, p < 0.001), but not
more antihypertensive medications. The most common
antihypertensive medications prescribed to diabetic
hypertensive patients were diuretics, ACE inhibitors, and
BB. Adjusted odds ratios for probability of BP control
for the diabetic hypertensive patient subset are included
in Table 5. Among diabetic hypertensive subjects (n =
1,656), African-Americans (OR = 0.441, 95% CI 0.312-
0.623) and Hispanics (OR = 0.580, 95% CI 0.391-0.859)
were significantly less likely to have controlled BP
compared to Caucasian subjects. Presence of renal dis-
ease (OR = 1.703, 95% CI 1.232-2.356) and increasing
total number of chronic prescription medications were
both associated with an increased probability of BP con-
trol in diabetic hypertensive patients. Use of CCB was
associated with a lower odds of controlled BP (OR =
0.672, 95% CI 0.471-0.958) as compared to diabetic
patients prescribed regimens not containing CCB.
Discussion
About 4 of every 5 (82%) patients in this study had 1
or more cardiometabolic risk factor, in addition to
hypertension. Almost half (49%) of hypertensive sub-
jects were also obese, and the proportion of hyperten-
sive patients with controlled BP decreased
continuously with increasing BMI. With the exception
of dyslipidemia alone, the co-occurrence of combina-
tions of CMRFCs significantly reduced the likelihood
of BP control as compared to hypertensive patients
without CMRFCs. Clearly diabetes, which was asso-
ciated with a BP control rate of 33%, and obesity,
which is interrelated with diabetes, have synergistic
roles in hypertension management, as evidenced by the
23% control rate for patients with both of these cardio-
metabolic conditions. However, logistic regression
results (Figure 1) suggest that individually, obesity and
diabetes (regardless of the presence or absence of the
other condition) both reduce the odds of controlled BP
among hypertensive patients. Patients with more
CMRFCs were prescribed a higher mean number of
antihypertensive medications than those without,
although the absolute difference (0.7) was not large
However, odds of BP control in this patient subset was
0.23 [95% CI 0.19-0.29] that of patients with hyperten-
sion and no other CMRFCs.
A recent study by Ong et. al. using 1999-2004
National Health and Nutrition Examination Survey




















0 -O -DM -HL 57.6% 42.7% 25.9% 31.1% 1197 (18.3%) 1.7 (1.1)
1 -O -DM +HL 60.3% 42.3% 29.1% 36.7% 1537 (23.5%) 1.8 (1.0)
+O -DM -HL 60.5% 50.6% 28.5% 31.8% 959 (14.7%) 1.9 (1.1)
-O +DM -HL 67.1% 45.7% 27.2% 38.7% 173 (2.7%) 2.0 (1.1)
2 +O -DM +HL 65.1% 53.3% 26.7% 39.8% 1178 (18.0%) 2.0 (1.1)
-O +DM +HL 78.7% 43.8% 29.5% 42.6% 441 (6.8%) 2.1 (1.2)
+O +DM -HL 73.5% 52.2% 32.7% 36.3% 245 (3.8%) 2.2 (1.3)
3 +O +DM +HL 82.1% 58.2% 32.1% 42.0% 797 (12.2%) 2.4 (1.2)
Total (n = 6,527) 65.3% 48.1% 28.5% 36.6% 6527 (100.0%) 2.0 (1.1)
O = obese (BMI ≥ 30); DM = diabetes; HL = dyslipidemia.
Row percentages by medication class do not total to100% since patients may be using more than one antihypertensive medication class.
Belletti et al. Cardiovascular Diabetology 2010, 9:7
http://www.cardiab.com/content/9/1/7
Page 6 of 11(NHANES) data found similar odds of BP control asso-
ciated with diabetes status as the current study [7].
However, the authors found that risk factors studied
were more common for women than men. Other studies
using different data sources have found the opposite
effect of gender [8]. Majernick et. al., in a practice-based
retrospective chart review study of 631 medication-trea-
ted hypertensive patients, found that female gender,
along with a higher Framingham Risk Score and pre-
sence of diabetes, were associated with reduced odds of
achieving BP control [11]. In contrast, while men in our
study population had a higher prevalence of diabetes,
CAD, renal disease, dyslipidemia, and prior MI, adjusted
odds of BP control were not different for men as com-
pared to women.
A recent study by Kaiser Permanente found that the
adjusted relative risk of cardiovascular events was high-
est for hypertensive patients with diabetes, hyperlipide-
mia, and obesity (RR = 2.80, 95% CI 2.48-3.17), and
patients with all 3 comorbid conditions had the highest
cumulative total medical-care costs [12]. Other research
has shown that CMRFCs result in substantial annual
medical expenditures in the US, even independently of
the cost of cardiovascular disease [8]. Sullivan et al
Figure 2 Relationship between BMI (kg/m
2) and Proportion of Entire Study Cohort (6,527) with Controlled BP*. The proportion of
hypertensive patients with controlled BP decreased with increasing patient BMI.
Table 3 Recommended antihypertensive medication class use among hypertensive patients with compelling
indications









Indicated Therapy Regimen % %
Diabetes Percentage of patients with HTN+DM prescribed ACEI/
ARB
78.3% 60.8% <0.001
Heart failure Percentage of patients with HTN+HF prescribed ACEI/
ARB or BB
88.7% 80.3% <0.001





Percentage of patients with HTN+CKD prescribed
ACEI/ARB
67.7% 65.1% ns
Post-stroke Percentage of patients with HTN+stroke-TIA-carotid
stenosis prescribed thiazide diuretic and ACEI
14.6% 13.7% ns
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CMRFCs (defined as diabetes, hypertension, hyperlipide-
mia, and/or overweight/obesity) in the US approached
$80 billion; for each individual with CMRFCs, $5477 in
annual medical expenditures was attributed to CMRFCs
[8]. Other work by Sullivan and colleagues has indicated
that CMRFCs also have a negative impact on health-
related quality of life [13] and work productivity [14]. In
a population of 5,512 employees, Burton et al. demon-
strated a deleterious effect on work productivity as the
number of metabolic risk factors per employee increased
along with a decrease in health perception [15]. Thus,
CMRFCs may affect individual self-health perception,
quality of life, productivity, and health care resources
consumed; furthermore, the impact may become more
pronounced as the number of CMRFCs in an affected
individual increases.
Metabolic syndrome, defined as the co-occurrence of
3o rm o r eo f5r i s kf a c t o r s( e l e v a t e dw a i s tc i r c u m f e r -
ence, elevated triglycerides, reduced high density lipo-
protein cholesterol, elevated BP, and elevated fasting
glucose), differs from the CMRFC concept in that
usually CMRFCs are defined by a clinical diagnosis of
hypertension, diabetes mellitus, dyslipidemia, and/or
obesity (based on body mass index). The prevalence of
metabolic syndrome [16], is estimated at 34% of the US
adult population [17]. Metabolic syndrome is associated
with an approximately doubled risk of atherosclerotic
cardiovascular disease events [16]. The assessment of
metabolic syndrome was outside the scope of the cur-
rent study, as some components that comprise meta-
bolic syndrome were not available for this study.
Assessment of CMRFCs may be more useful and prac-
ticable in retrospective studies, as several of the
Table 4 Diabetic Cohort (n = 1,656) Clinical and Demographic Characteristics by BP Control Status
Uncontrolled BP (n = 1,105) Controlled BP (<130/80 mmHg) (n =
551)
Total (N = 1,656)
Age (years; mean, SD) 64.8 (12.3) 66.8 (12.0) (p < 0.01) 65.4 (12.2)
Gender- Male (n,%) 542 (65.5%) 286 (34.5%) 828 (50.6%)
Female (n,%) 549 (67.9%) 259 (32.1%) (p=NS) 808 (49.4%)
BMI (kg/m
2; mean, SD) 33.5 (7.5) 32.7 (7.8) (p < 0.05) 33.2 (7.6)
Normal (n,%) 118 (59.9%) 79 (40.1%) 197 (11.9%)
Overweight (n,%) 276 (66.2%) 141 (33.8%) 417 (25.2%)
Obese (n,%) 521 (68.1%) 244 (31.9%) 765 (46.2%)
Morbidly obese (n,%) 190 (68.6%) 87 (31.4%) 277 (16.7%)
Racial/ethnic background (n,%) (p < 0.001)
Caucasian 452 (60.6%) 294 (39.4%) 746 (45.0%)
African-American 211 (78.7%) 57 (21.3%) 268 (16.2%)
Hispanic 112 (71.8%) 44 (28.2%) 156 (9.4%)
Unknown/not documented 330 (67.9%) 156 (32.1%) 486 (29.3%)
Prescribed lifestyle modifications to
control BP (%)
706 (64.8%) 353 (65.0%) 1059(64.8%)
Number of antihypertensive
medications (mean, SD)
2.2 (1.2) 2.3 (1.2) (p=NS) 2.3 (1.2)
Number of chronic medications
(mean, SD)
7.1 (3.6) 8.1 (4.0) (p < 0.001) 7.4 (3.8)
Antihypertensive medication class Use among uncontrolled patients (n
= 1,105)
Use among controlled patients (n =
551)
Use among all patients (n
= 1,656)
ACEI/ARB 75.7% 81.7% (p < 0.02) 78.3%
BB 39.7% 43.6% (p=NS) 41.0%
CCB 33.4% 26.1% (p < 0.01) 31.0%
Any diuretic 50.6% 55.4% (p=NS) 52.2%
% with BP control among patients
with condition
% with BP control among patients
without condition
Hyperlipidemia (%) 35.1% 27.8% (p = 0.006)
Renal disease/insufficiency (%) 46.7% 31.4% (p < 0.001)
CAD without MI (%) 38.4% 32.1% (p < 0.04)
ACEI and/or ARB use (%) 34.7% 28.1% (p < 0.03)
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available for chart review studies.
The presence of CMRFCs may have an impact on the
specific choice of antihypertensive medication class pre-
scribed by the physician for the hypertensive patient.
Physician adherence to guidelines recommending use of
an ACEI or ARB in hypertensive diabetic patients in our
study was high. About one-quarter of our hypertensive
patient population had diabetes, and 78% of these
patients were prescribed an ACEI and/or ARB. Our
findings are similar to those from other research which
has estimated that 85% of diabetic hypertensive patients
with renal involvement, and 71% of those without renal
involvement, are prescribed an ACEI and/or ARB [18].
Both clinical trials and “real-world” studies indicate that
obese hypertensive patients are more difficult to treat
than their non-obese counterparts [19]. In this study,
the presence of obesity did not seem to have an effect
on choice of antihypertensive medication regimen.
Adherence to recommended treatment regimens for
hypertensive patients with the compelling indications of
heart failure (89%) or history of myocardial infarction
(88%) was high in our study population.
About half of our hypertensive patient population was
obese, compared to about 40% of hypertensive subjects
from NHANES 1999-2002 [6]. We observed a decreas-
ing probability of BP control associated with increasing
patient BMI. Obesity has been increasing in the past
several decades, from 22.9% in NHANES 1988-1994 to
32.2% using NHANES 2003-2004 [20]. Framingham
Study data has shown that obesity and weight gain are
the most important determinants of the development of
hypertension, as well as predicting that other cardiovas-
cular risk factors will cluster with elevated BP [3]. Our
study population exhibited a clear, consistent relation-
ship between increasing BMI and BP control, but little
variation in total number of antihypertensive medica-
tions used. Since the prevalence of obesity in the US is
increasing among most demographic subgroups [4],
therapeutic management which targets obese hyperten-
sive patients is critical to successful BP control. The
higher prevalence of obesity among hypertensive
Table 5 Odds ratios for BP control among diabetic hypertensive study population (n = 1,656)
Variable Levels Odds Ratio relative to first row 95% Confidence Interval
Age 1.007 0.997, 1.017
Gender Male
Female 1.102 0.886, 1.371
Race/ethnicity Caucasian
African-American 0.441 0.312, 0.623
Hispanic 0.580 0.391, 0.859
Missing/other 0.728 0.566, 0.937
Obese 0.818 0.647, 1.036
Dyslipidemia 1.134 0.874, 1.472
Renal disease 1.703 1.232, 2.356
Number of antihypertensive medication classes 1
None 1.619 0.790, 3.316
2 1.162 0.774, 1.744
3 0.795 0.428, 1.476
>=4 1.188 0.530, 2.662
Total number of chronic prescriptions 0-3
4-6 2.069 1.373, 3.117
7-9 2.387 1.564, 3.645
>=10 2.704 1.740, 4.202
Any ACEI/ARB use No
Yes 1.343 0.921, 1.959
Any CCB use No
Yes 0.672 0.471, 0.958
Any diuretic use No
Yes 1.174 0.810, 1.703
Any BB use No
Yes 0.962 0.687, 1.348
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regarding the health-care seeking status of our study
population, or may be related to the increase in obesity
prevalence overall in the US that may not yet be
reflected in available data sources, which reflect data
from 2004. It is projected that if current obesity trends
continue, by the year 2015, 75% of adults would be
overweight or obese [21].
Although our study provides useful information about
the prevalence of CMRFCs and their impact on hyper-
tension management, it is important to consider several
limitations. A considerable number of patients had miss-
ing data for several variables, including race/ethnicity
and smoking status. Other potential factors, including
duration or etiology of hypertension, duration of antihy-
pertensive medication use, severity of concomitant con-
ditions (such as diabetes, CHF, and CAD), prior
antihypertensive medication failure, and type of health
insurance coverage were not available for analysis. Other
factors which were beyond the scope of the current
s t u d yw h i c hm a yh a v ep l a y e dar o l ei nB Pc o n t r o l
include dosing optimization of currently prescribed drug
regimens, patient antihypertensive medication compli-
ance, and adherence to diet and exercise recommenda-
tions. BP measurements were obtained retrospectively
via chart review, and thus these measurements were not
standardized, nor were they able to be defined prospec-
tively. While we did not examine potential seasonal
effects on blood pressure, we do not expect that such an
effect would impact specific patient CMRFCs differently
or substantially alter study results. The cross-sectional
study design employed does not permit the determina-
tion of a cause-and-effect relationship between BP con-
trol and medication use. While our hypertensive
population was geographically distributed across all
regions of the US, it is not representative of the US
hypertensive population as a whole. Furthermore, some
of the discrepancies when comparing our results to
NHANES results may, in part, be due to the fact that
our patient sample is a healthcare-seeking population, as
participating patients were all receiving care from a phy-
sician to manage hypertension, in contrast to data from
s o u r c e ss u c ha sN H A N E S ,w h i c h ,w h i l ew e i g h t e dt ob e
representative of the US demographically, includes per-
sons not receiving routine medical care, as well as
undiagnosed hypertensive individuals.
Conclusions
Our study design enabled us to assess the co-occur-
rence of cardiometabolic risk factors in a large hyper-
tensive study population representing a “real-world”
setting among physician practices across the US, and
to estimate the impact of specific overlapping risk fac-
tors on BP control. 82% of our hypertensive study
population had one or more additional cardiometabolic
risk factors: almost half were obese, and 1 in 4 had
diabetes. With the exception of patients with only
hypertension and dyslipidemia, patients with 1 or more
CMRFC were less likely to have controlled BP. The
odds of BP control for hypertensive patients with all 3
CMRFCs were 23% of the odds of control for hyper-
tensive patients with no CMRFCs, yet, on average,
patients with all 3 CMRFCs were prescribed less than
1 additional antihypertensive medication class than
patients with no CMRFCs. The increasing obesity pre-
valence and the deleterious effect of obesity on BP
control is a key public health concern. Health care
providers and public health officials must consider the
potential compounding effects of increased obesity on
BP control in future years. The high prevalence of
CMRFCs in hypertensive patients presents a challenge
to the management of BP, and should be considered
when selecting each patient’s most appropriate antihy-
pertensive medication regimen, with consideration
given to both specific medication classes comprising
the regimen, as well as the overall intensity of the ther-
apeutic regimen (dosage strength and/or number of
medications used in combination). More aggressive
hypertension management strategies for obese and/or
diabetic hypertensive patients are warranted to
improve BP control in these difficult-to-treat patient
subgroups.
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